Results 81 to 90 of about 5,550 (180)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera [PDF]

Blood Cancer Journal, 2021
Dan Liu, Zefeng Xu, Peihong Zhang, Tiejun Qin, Bing Li, Shiqiang Qu, Lijuan Pan, Wenyu Cai, Jinqin Liu, Huijun Wang, Qi Sun, Xiujuan Sun, Meng Jiao, Qingyan Gao, Zhongxun Shi, Huijun Huang, Gang Huang, Robert Peter Gale, Zhijian Xiao   +18 more
openaire   +3 more sources

Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells

Cell Communication and Signaling
Background The JAK2-V617F mutation is the most frequent driver mutation in a group of malignant hematopoietic disorders called myeloproliferative neoplasms (MPN).
Conny K. Baldauf, Corinna Fahldieck, Alexa Angenstein, Sönke Weinert, Mariam Hakobyan, Daniel B. Lipka, Tobias R. Haage, Vikas Bhuria, Martin Böttcher, Dimitrios Mougiakakos, Burkhart Schraven, Thomas Fischer   +11 more
doaj   +1 more source

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos, Juliana Corrêa da Costa Ribeiro, Neusa Pereira Silva, Janete Cerutti, Maria Regina Regis da Silva, Maria de Lourdes Lopes Ferrari Chauffaille   +5 more
doaj   +1 more source

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases

Haematologica, 2009
JAK2 V617F, identified in the majority of patients with myeloproliferative neoplasms, tyrosine phosphorylates SOCS3 and escapes its inhibition. Here, we demonstrate that the JAK2 exon 12 mutants described in a subset of V617F-negative MPN cases, also ...
Joanne Elliott, Yvonne Suessmuth, Linda M. Scott, Krystyna Nahlik, Mary Frances McMullin, Stefan N. Constantinescu, Anthony R. Green, James A. Johnston   +7 more
doaj   +1 more source

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders

Revista Brasileira de Hematologia e Hemoterapia, 2008
Síndromes mieloproliferativas (SMPs) são doenças hematopoéticas de origem clonal que apresentam amplificação de uma ou mais linhagens mielóides. Policitemia vera (PV), trombocitemia essencial (TE), mielofibrose idiopática (MF) e leucemia mielóide crônica (LMC) são consideradas SMPs clássicas e apresentam características clínicas e biológicas comuns. Ao
Bárbara C. R. Monte-Mór, Fernando F. Costa   +1 more
openaire   +1 more source

JAK2 V617F Mutation and Large Cerebral Artery Disease in Patients with Myeloproliferative Neoplasms. [PDF]

J Atheroscler Thromb, 2023
Oyama N, Iwamoto T, Doyu K, Miyazato S, Okazaki T, Yamada S, Kondo T, Wada H, Yagita Y.   +8 more
europepmc   +1 more source

Hypereosinophilic Syndrome with Endomyocarditis: Identification by Next-Generation Sequencing of the JAK2-V617F Mutation. [PDF]

Eur J Rheumatol, 2023
Tesfamicael R, Aung T, Domin Lee T, Brahn E.   +3 more
europepmc   +1 more source

THE JAK2 V617F MUTATION IN LUNG CANCER: CAVEAT EMPTOR

Experimental Oncology, 2018
As acquisition of the JAK2 V6 7F is considered to e restricted to myeloid malignancies the recurrent identification of this mutation in non-small cell lung cancer NSCLC merits discussion particularly in the light of accumulating evidence which suggests that the JAK2 V6 7F may not e a true driver mutation of NSCLC.
openaire   +2 more sources

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes. [PDF]

Blood Adv, 2023
Rafati M, Brown DW, Zhou W, Jones K, Luo W, St Martin A, Wang Y, He M, Spellman SR, Wang T, Deeg HJ, Gupta V, Lee SJ, Bolon YT, Chanock SJ, Machiela MJ, Saber W, Gadalla SM.   +17 more
europepmc   +1 more source

Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation. [PDF]

J Taibah Univ Med Sci, 2022
Rahman KH, Surboyo MDC, Radithia D, Parmadiati AE, Wihandono A, Ernawati DS.   +5 more
europepmc   +1 more source